Ripretinib (QINLOCK®) is a next-generation targeted therapy that marks a significant advancement in the treatment of gastrointestinal stromal tumors (GIST). Designed to address the challenges of tumor heterogeneity and drug resistance, ripretinib offers a vital treatment option for patients with advanced disease who have progressed after multiple lines of therapy.
With its innovative...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
